Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany

PHASE4CompletedINTERVENTIONAL
Enrollment

214

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

March 31, 2016

Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
DRUG

dimethyl fumarate

capsules administered according to the prevailing product label

Trial Locations (19)

Unknown

Research Site, Augsburg

Research Site, Bamburg

Research Site, Bayreuth

Research Site, Berlin

Research Site, Bochum

Research Site, Bonn

Research Site, Erbach im Odenwald

Research Site, Erlangen

Research Site, Freiburg im Breisgau

Research Site, Hamburg

Research Site, Leipzig

Research Site, Marburg

Research Site, Minden

Research Site, Mittweida

Research Site, München

Research Site, Münster

Research Site, Osnabrück

Research Site, Potsdam

Research Site, Siegen

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY

NCT02125604 - Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany | Biotech Hunter | Biotech Hunter